Medline Inc. company mark

Medline Inc. Annual Report FY2026

Official PDF · AI Summary · Financial Analysis
Official Annual + Quarterly Filings · AI Business Intelligence
NASDAQ/NYSE: MDLN
Sector: Healthcare
Industry: Medical Instruments & Supplies
Source: SEC EDGAR
Last Updated: 17 Jun 2026
Business Intelligence Report Verdict
Average
Outlook: Neutral

Quality Scores

Latest Quarterly Earnings Summary

No quarterly summary available yet.

AI Summary

Medline Inc. (MDLN) operates as a dominant force in healthcare manufacturing and distribution, evidenced by its massive $28.43B revenue base. The FY2025 data reveals a company with significant operational scale and strong cash generation capabilities, though it reported a marginal net loss of $7M. This disconnect between a $2.21B operating income and a net loss suggests heavy non-operating expenses, likely stemming from interest costs or tax adjustments related to its private-to-public transition. With $38.48B in assets and $10.74B in equity, the company maintains a substantial footprint in…

Key Changes in FY2026

The business has evolved into a massive healthcare supply chain powerhouse, achieving 28.43B in annual revenue by 2025. The data suggests a transition from a pure-play distributor to a vertically integrated manufacturer and logistics provider, as evidenced by the significant asset base of 38.48B. Recent strategic impacts involve scaling operations to handle high-volume institutional demand, although this has resulted in current-period net losses. The infrastructure is now capable of supporting significant 'Hospital-at-Home' and clinical supply trends. The evolution indicates a move toward becoming an indispensable partner in the US healthcare system. Despite the scale, the 2025 results show a focus on volume over immediate bottom-line profitability during this expansion phase.

Management Commentary

Medline's management successfully oversees a logistics-heavy operation with $28.43B in annual throughput, demonstrating high operational competence. The reporting transparency is moderate, though the gap between operating and net income requires clearer MD&A articulation for public shareholders. Management appears focused on scaling the healthcare supply chain, a traditionally low-margin but high-moat business. The vision seems aligned with domesticating the medical supply chain post-pandemic, though efficiency at the net level remains a work in progress. Further evaluation of executive compensation is required to determine alignment with minority shareholders.

Financial Highlights

While the top-line revenue of $28.43B is impressive, the 2025 net margin of -0.02% indicates extreme bottom-line pressure despite a healthy 7.7% operating margin. The discrepancy between $2.21B in operating income and a $7M net loss points to a heavy debt service burden or significant one-time impairments. Asset turnover remains moderate, but the equity base of $10.74B is leveraged against a $38.48B asset base, suggesting a debt-to-equity profile that requires monitoring. The lack of 10-year historical data in the current filing restricts the ability to confirm long-term compounding trends. However, the sheer scale of operations provides a defensive floor against industry volatility.

Major Opportunities

  • Massive revenue scale exceeding $28B
  • Strong top-line growth at 10% YoY
  • Positive and growing CFO

Major Risks

  • Persistent net losses over 3-year period
  • Thin operating margins typical of distributors
  • High competitive intensity from Cardinal/McKesson

About This Annual Report

The Medline Inc. FY2026 Annual Report is the company's flagship annual disclosure, filed with SEC EDGAR. It covers the full-year business review, management discussion & analysis (MD&A), audited financial statements, director's report, corporate governance report, auditor's report, risk factors, capital allocation, subsidiaries, related-party transactions and ESG initiatives. This page consolidates the official PDF and an AI-generated summary so investors can quickly grasp what changed vs. prior years — sales growth, margin trend, cash flow quality, capex, dividends and management outlook — without having to read the entire filing.

Why Use AI?

  • Summarises hundreds of pages into a focused executive briefing
  • Identifies year-on-year key changes automatically
  • Extracts management commentary and tone
  • Highlights top risks and opportunities
  • Compares business evolution vs. earlier years
  • Answers your questions in plain English via Ask AI

Frequently Asked Questions

Related Research

AI Top Insights — Premium

Unlock deeper AI Top Insights, advanced comparisons, downloadable reports and premium features.